Dovitinib enhances temozolomide efficacy in glioblastoma cells

The multikinase inhibitor and FDA‐approved drug dovitinib (Dov) crosses the blood–brain barrier and was recently used as single drug application in clinical trials for GB patients with recurrent disease. The Dov‐mediated molecular mechanisms in GB cells are unknown. We used GB patient cells and cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Thanasupawat, Thatchawan, Natarajan, Suchitra, Rommel, Amy, Glogowska, Aleksandra, Bergen, Hugo, Krcek, Jerry, Pitz, Marshall, Beiko, Jason, Krawitz, Sherry, Verma, Inder M., Ghavami, Saeid, Klonisch, Thomas, Hombach‐Klonisch, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537714/
https://www.ncbi.nlm.nih.gov/pubmed/28500786
http://dx.doi.org/10.1002/1878-0261.12076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537714/
https://www.ncbi.nlm.nih.gov/pubmed/28500786
http://dx.doi.org/10.1002/1878-0261.12076

Ejemplares similares